



HAL
open science

Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex

Mark Nellist, Marianne Hoogeveen-Westerveld, Marjolein Wentink, Diana van den Heuvel, Melika Mozaffari, Rosemary Ekong, Sue Povey, Johan T. den Dunnen, Kay Metcalfe, Stephanie Vallee, et al.

► To cite this version:

Mark Nellist, Marianne Hoogeveen-Westerveld, Marjolein Wentink, Diana van den Heuvel, Melika Mozaffari, et al.. Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex. *Human Mutation*, 2011, 32 (4), pp.424. 10.1002/humu.21451 . hal-00620580

HAL Id: hal-00620580

<https://hal.science/hal-00620580>

Submitted on 8 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Functional assessment of variants in the TSC1 and TSC2
genes identified in individuals with Tuberous Sclerosis
Complex**

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0472.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	01-Dec-2010
Complete List of Authors:	<p>Nellist, Mark; Erasmus Medical Center, Clinical Genetics Hoogeveen-Westerveld, Marianne; Erasmus MC Wentink, Marjolein; Erasmus MC van den Heuvel, Diana; Erasmus MC Mozaffari, Melika; Erasmus MC Ekong, Rosemary; University College Povey, Sue; University College den Dunnen, Johan; Leiden University Medical Center, Human & Clinical Genetics Metcalfe, Kay; Central Manchester University Hospitals NHS Foundation Trust Vallee, Stephanie; Dartmouth-Hitchcock Medical Center Krüger, Stefan; Gemeinschaftspraxis für Humangenetik, Center for Human Genetics Shashi, Vandana; Duke University Bergoffen, JoAnn; Kaiser Permanente San Jose Medical Center Elmslie, Frances; St. George's Hospital Kwiatkowski, David; Brigham and Women's Hospital, Medicine Sampson, Julian; Cardiff University, Medical Genetics Vidales, Concha; Policlínica Gipuzka Dzarir, Jacinta; The Prince of Wales Hospital Garcia-Planells, Javier; University of Valencia Dies, Kira; Children's Hospital Maat-Kievit, Anneke; Erasmus Medical Center, Department of Clinical Genetics van den Ouweland, Ans M.W.; ErasmusMC, Clinical Genetics Halley, Dicky; Erasmus MC</p>
Key Words:	tuberous sclerosis complex, TSC1, TSC2, unclassified variants

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title page:[Human Mutation submission]

Functional assessment of variants in the *TSC1* and *TSC2* genes identified in individuals with Tuberous Sclerosis Complex

Marianne Hoogveen-Westerveld¹, Marjolein Wentink¹, Diana van den Heuvel¹, Melika Mozaffari¹, Rosemary Ekong², Sue Povey², Johan T. den Dunnen³, Kay Metcalfe⁴, Stephanie Vallee⁵, Stefan Krueger⁶, JoAnn Bergoffen⁷, Vandana Shashi⁸, Frances Elmslie⁹, David Kwiatkowski¹⁰, Julian Sampson¹¹, Concha Vidales¹², Jacinta Dzarir¹³, Javier Garcia-Planells¹⁴, Kira Dies¹⁵, Anneke Maat-Kievit¹, Ans van den Ouweland¹, Dicky Halley¹ and Mark Nellist¹

¹Department of Clinical Genetics, Erasmus Medical Centre, 3015 GE Rotterdam, The Netherlands.

²Research Department of Genetics, Evolution and Environment, University College London, London NW1 2HE, U.K.

³Department of Human and Clinical Genetics, Leiden University Medical Centre, 2333 ZC Leiden, The Netherlands.

⁴Department of Genetic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, U.K.

⁵Department of Clinical Genetics, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, U.S.A.

⁶Center for Human Genetics, Gutenbergstr. 5, D-01307 Dresden, Germany.

⁷Department of Genetics, Kaiser Permanente San Jose Medical Center, 5755 Cottle Road, San Jose, CA 95123, U.S.A.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

⁸Department of Pediatrics, Duke University Medical Center, Durham, NC, U.S.A.

⁹Department of Medical Genetics, St. George's Hospital, London SW17 0RE, U.K.

¹⁰Translational Medicine Division, Brigham and Womens Hospital, Boston MA 02115,
U.S.A.

¹¹Institute of Medical Genetics, Cardiff University, Heath Park, Cardiff CF4 4XN, U.K.

Deleted: of Wales College of Medicine

¹²Department of Molecular Genetics, Policlinica Gipuzka, 20009 San Sebastian, Spain.

¹³Department of Molecular Genetics, The Prince of Wales Hospital, Randwick,
Australia.

¹⁴ Institute of Medical Genomics, University of Valencia, Valencia, Spain.

¹⁵ Department of Neurology, Children's Hospital Boston, Boston MA 02115, U.S.A.

To whom correspondence should be addressed: Dr. Mark Nellist, Department of
Clinical Genetics, Erasmus Medical Centre, Dr. Molewaterplein 50, 3015 GE
Rotterdam, The Netherlands, Tel: +31 10 7044628; Fax: +31 10 7044736; email:
m.nellist@erasmusmc.nl

Running title: Functional assessment of TSC1 and TSC2 variants

Abstract

The effects of missense changes and small in-frame deletions and insertions on protein function are not easy to predict and the identification of such variants in individuals at risk of a genetic disease can complicate genetic counselling. One option is to perform functional tests to assess whether the variants affect protein function. We have used this strategy to characterise variants identified in the *TSC1* and *TSC2* genes in individuals with, or suspected of having, Tuberous Sclerosis Complex (TSC). Here we present an overview of our functional studies on 45 *TSC1* and 107 *TSC2* variants. Using a standardised protocol we classified 16 *TSC1* variants and 70 *TSC2* variants as pathogenic. In addition we identified 8 putative splice site mutations (5 *TSC1* and 3 *TSC2*). The remaining 24 *TSC1* and 34 *TSC2* variants were classified as probably neutral.

Keywords: tuberous sclerosis complex, *TSC1*, *TSC2*, unclassified variants

Introduction

Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder characterised by the development of hamartomas in a variety of organs and tissues, most notably the brain, skin and kidneys [Gomez et al., 1999]. Most individuals with TSC have epilepsy and many suffer from cognitive impairments and/or autism-spectrum disorders. Mutations in either the *TSC1* gene on chromosome 9q34 ([OMIM #605284](#)) [van Slegtenhorst et al., 1997], or the *TSC2* gene on chromosome 16p13.3 ([OMIM #191092](#)) [European Chromosome 16 Tuberous Sclerosis Consortium, 1993], cause TSC and comprehensive mutation screens in TSC patients have identified a wide variety of pathogenic mutations [Jones et al., 1999; Niida et al., 1999; Dabora et al., 2001; Sancak et al., 2005; Au et al., 2007]. Most *TSC1* and *TSC2* mutations result in premature termination of the respective open-reading frame and complete inactivation of the mutated allele. However, approximately 25% of the mutations identified in the *TSC2* gene and 1% of the mutations identified in *TSC1*, are non-terminating missense changes or small in-frame deletions or insertions [Sancak et al., 2005]. The consequences of such non-terminating changes are not easy to predict with certainty, making it difficult to distinguish disease-causing mutations from neutral (non-pathogenic) variants. In a cohort of 490 putative TSC cases, we identified 29 variants (6% of the total) that could not be classified as either pathogenic or neutral from the available clinical and genetic data [Sancak et al., 2005]. In such cases, *in vitro* functional comparisons between the wild-type and variant proteins can help determine whether an unclassified variant (UV) is pathogenic or not [Nellist et al., 2008].

The *TSC1* and *TSC2* gene products, TSC1 and TSC2, interact to form a protein complex that integrates multiple growth factor- and energy-dependent signals to help

Deleted:

Deleted: *TSC2* mutations are generally associated with a more severe TSC phenotype [Dabora et al., 2001]. However, there are several reports of families where specific *TSC2* missense mutations cosegregate with apparently mild forms of the disease [Khare et al., 2001; O'Connor et al., 2003; Mayer et al., 2004; Jansen et al., 2006], consistent with the proposal that specific types of *TSC1* or *TSC2* mutation may help determine the clinical course of the disease [de Vries and Howe, 2007]. It would be useful to be able to identify *TSC1* and *TSC2* variants that have reduced activity, as opposed to being completely inactive, and that might be less likely to lead to a severe TSC phenotype.

1 control cell growth [Inoki and Guan, 2009]. The N-terminal region of TSC2 is required
2
3
4 for binding TSC1 [Li et al., 2004], while the TSC2 C-terminal region contains the
5
6 active site of the complex, an "asparagine-thumb" GTPase activating protein (GAP)
7
8 domain [Daumke et al., 2004]. The TSC1-TSC2 complex stimulates the GTPase
9
10 activity of RHEB to promote the conversion of active, GTP-bound RHEB to inactive
11
12 RHEB-GDP and thereby prevent the RHEB-GTP-dependent stimulation of the
13
14 mammalian target of rapamycin (mTOR) complex 1 (TORC1) [Li et al., 2003]. In cells
15
16 lacking either *TSC1* or *TSC2*, the downstream targets of TORC1, including elongation
17
18 factor 4E binding protein 1 (4E-BP1), p70 S6 kinase (S6K) and ribosomal protein S6,
19
20 are constitutively phosphorylated [Zhang et al., 2003; Kwiatkowski et al., 2001].
21

22 The effects of specific amino acid changes on TSC1-TSC2 complex formation,
23
24 on the activation of RHEB GTPase activity by the complex, and on the phosphorylation
25
26 status of 4E-BP1, S6K and S6, have been investigated [Nellist et al., 2001; Inoki et al.
27
28 2002, Tee et al, 2002]. Previously, we used immunoblotting, double-label
29
30 immunofluorescent microscopy, in-cell Western analysis and GAP assays to study the
31
32 effects of 47 *TSC2* missense and in-frame insertions/deletions and 26 *TSC1* missense
33
34 and in-frame insertions/deletions on TSC1-TSC2 activity [Nellist et al., 2005; Jansen et
35
36 al., 2006, Jansen et al., 2008, Nellist et al., 2008, Nellist et al., 2009; Coevoets et al.,
37
38 2009; Mozaffari et al., 2009]. Pathogenic missense changes in the N-terminal region of
39
40 TSC1 (amino acids 50 - 224) reduced TSC1 stability [Nellist et al., 2009; Mozaffari et
41
42 al., 2009], while pathogenic TSC2 missense changes had distinct effects on the TSC1-
43
44 TSC2 complex, depending on the region of TSC2 that was affected. Some TSC2 amino
45
46 acid substitutions prevented TSC1-TSC2 complex formation while others did not affect
47
48 TSC1-TSC2 binding, but still inactivated the complex [Nellist et al., 2005]. Here we
49
50 compare 73 previously tested variants to 79 new variants (19 *TSC1* and 60 *TSC2*) using
51
52
53
54
55
56
57
58
59
60

Deleted: the

Deleted: with

1
2 a standardised protocol. To assess the effects of the variants on both the formation and
3 activity of the TSC1-TSC2 complex we decided to use immunoblotting followed by
4 infra-red scanner-based detection. In our experience, double-label microscopy and GAP
5 assays were too labour-intensive and/or unreliable for routine use and, although the in-
6 cell Western was a simple and reliable assay [Coevoets et al., 2009], it required large
7 amounts of (expensive) antibodies and did not provide information on the TSC1-TSC2
8 interaction.
9

10 Our aim was to investigate the reliability of the assay, the degree of concordance
11 between the *in vitro* results and computer-based predictive methods and, ultimately, to
12 use the results of the functional assessment to determine whether variants identified in
13 individuals with, or suspected of having, TSC were pathogenic. To assess the reliability
14 of our functional studies we compared our results to the classifications of the variants
15 listed in the *TSC1* and *TSC2* Leiden Open Variation Databases (LOVD)
16 (<http://www.lovd.nl/TSC1>; <http://www.lovd.nl/TSC2>). Furthermore, we hoped to gain
17 insight into the structural properties of TSC1 and TSC2 by comparing the properties of
18 the different variants.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Materials and Methods**

39 *TSC1 and TSC2 variants*

40 The relative positions of the variants selected for functional assessment are
41 shown in Figure 1. All variants are listed in Supporting Tables S1, S2 and S3. The
42 variants were compared to wild-type TSC1 (Genbank AF013168.1; GI: 2331280) and
43 TSC2 (Genbank X75621; GI:450351), as originally described [van Slegtenhorst et al.,
44 1997; European Chromosome 16 Tuberous Sclerosis Consortium, 1993] and it is
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: Previously untested variants are indicated in Tables 1., 2. and 3. It is important to note that t

Deleted: TSC2

Deleted: .

1
2 therefore important to note that the *TSC2* wild-type lacks the amino acids encoded by
3
4 the alternatively spliced exon 31. The amino acid numbering according to the *TSC2*
5
6 LOVD (<http://www.lovd.nl/TSC2>), where this differs from the original numbering due
7
8 to the inclusion of exon 31, is given in Supporting Table S3.
9

Deleted: Th

Deleted: is isoform

Deleted: *TSC2* database

10 Nucleotide numbering reflects the cDNA numbering with +1 corresponding to
11
12 the A of the ATG translation initiation codon in the reference sequence, according to
13
14 journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
15
16

17 18 *Constructs and antisera*

19
20 Expression constructs encoding the *TSC1* and *TSC2* variants were derived from
21
22 the wild-type expression constructs [Nellist et al., 2005] using the QuikChange site-
23
24 directed mutagenesis kit (Stratagene, La Jolla, U.S.A.). In each case the complete open
25
26 reading frame of the mutated construct was verified by sequence analysis. DNA was
27
28 prepared using the Plasmid Plus Midi Purification kit (Qiagen, Venlo, The
29
30 Netherlands). In most cases, multiple clones were isolated, verified and used for the
31
32 assays described below. Other constructs used in this study have been described
33
34 previously [Nellist et al., 2005]. Antibodies were purchased from Cell Signaling
35
36 Technology (Danvers, U.S.A.) (1A5, anti T389 phospho-S6K mouse monoclonal;
37
38 9B11, anti-myc tag mouse monoclonal; anti-myc tag rabbit polyclonal), Li-Cor
39
40 Biosciences (Lincoln, U.S.A.) (goat anti-rabbit 680 nm and goat anti-mouse 800 nm
41
42 conjugates) or DAKO (Glostrup, Denmark) (cyanine (Cy2)-coupled secondary
43
44 antibodies against mouse immunoglobulins), or have been described previously [van
45
46 Slegtenhorst et al., 1998].
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: check

1
2 *Transfection-based immunoblot assay for functional assessment of TSC1 and TSC2*
3
4 *variants*

5
6 TSC1 and TSC2 variants were assayed using essentially the same protocol. HEK
7
8 293T cells were seeded into 24-well plates and grown overnight in Dulbecco's modified
9
10 Eagle medium (DMEM) (Lonza, Verviers, Belgium) supplemented with 10% foetal
11
12 bovine serum, 50 U/ml penicillin and 50 µg/ml streptomycin in a 10% carbon dioxide
13
14 humidified incubator. Cells at 80 - 90% confluency were transfected with 0.2 µg TSC2
15
16 expression construct, 0.4 µg TSC1 expression construct and 0.1 µg S6K expression
17
18 construct using 2.1 µg polyethyleneimine (Polysciences Inc., Warrington, U.S.A.) in
19
20 DMEM, as described previously [Coevoets et al., 2009]. For control transfections,
21
22 pcDNA3 vector DNA was added to make a total of 0.7 µg DNA per transfection. Cells
23
24 expressing the TSC2 variants were compared to cells expressing wild-type TSC1-TSC2,
25
26 a known pathogenic variant (TSC2-R611Q [Nellist et al., 2005]), TSC1 and S6K only
27
28 (no TSC2), and cells transfected with vector DNA only (control). Cells expressing the
29
30 TSC1 variants were compared to wild-type TSC1-TSC2, a known pathogenic variant
31
32 (TSC1-L117P [Nellist et al., 2009]), TSC2 and S6K only (no TSC1), TSC1 and S6K
33
34 only (no TSC2) and cells transfected with vector DNA only (control).
35

36 After 4 hours the transfection mixtures were replaced with DMEM
37
38 supplemented with 10% foetal bovine serum, 50 U/ml penicillin and 50 µg/ml
39
40 streptomycin. Twenty-four hours after transfection the cells were transferred to ice,
41
42 washed with phosphate-buffered saline (PBS) (4°C) and harvested in 75 µl lysis buffer
43
44 (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM NaF and 1% Triton X100, containing
45
46 a protease inhibitor cocktail (Complete, Roche Molecular Biochemicals, Woerden, The
47
48 Netherlands)). After centrifugation (10 000 g for 10 minutes at 4°C), the supernatant
49
50 fractions were recovered, diluted in loading buffer and incubated at 96°C for 5 minutes
51
52
53
54
55

Deleted: In each experiment up to 20
TSC1 or TSC2 variants were tested.

1
2 prior to electrophoresis on Criterion™ 4-12% SDS-PAGE gradient gels (Bio-Rad,
3 Hercules, U.S.A.). Proteins were transferred to nitrocellulose membranes according to
4 the manufacturer's recommendations.
5
6
7

8 Blots were blocked for 1 hour at room temperature with 5% low-fat milk
9 powder (Campina Melkunie, Eindhoven, The Netherlands) in PBS and incubated
10 overnight at 4°C with the following primary antibodies: 1/15 000 dilution of 1895
11 (rabbit polyclonal against TSC2 [van Slegtenhorst et al., 1998]), 1/5 000 dilution of
12 2197 (rabbit polyclonal against TSC1 [van Slegtenhorst et al., 1998]), 1/5 000 dilution
13 of a rabbit polyclonal against the myc epitope tag and 1/2 000 dilution of 1A5 (mouse
14 monoclonal against p70 S6 kinase (S6K) phosphorylated at amino acid T389).
15
16
17
18
19
20
21

22 Antibodies were diluted in PBS containing 0.1 % Tween 20 (PBST) (Sigma-Aldrich
23 Fine Chemicals, Poole, U.K). After washing 3 times for 5 minutes in PBST, the blots
24 were incubated for 1 hour at room temperature in the dark in PBST containing 1/10 000
25 dilutions of goat anti-rabbit 680 nm and goat anti-mouse 800 nm secondary antibodies.
26
27 After washing 3 times for 5 minutes in PBST and once in PBS, the blots were scanned
28 using the Odyssey™ Infrared Imager (Li-Cor Biosciences) at default intensity, medium
29 quality, 169 µm resolution with 0 mm focus offset. To estimate the expression levels of
30 the different proteins and the ratio of T389-phosphorylated S6K to total S6K, in the
31 presence of the different TSC1 and TSC2 variants, the scans were analysed using the
32 Odyssey quantification software. The integrated intensities of the protein bands were
33 determined using default settings with the 3 pixel width border mean average
34 background correction method. To correct for the detection of endogenous proteins, we
35 subtracted the signals detected in control cells (transfected with vector DNA only) from
36 the corresponding TSC2, TSC1, S6K and T389-phosphorylated S6K signals for all
37 variants.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Immunofluorescent detection of TSC1 variants

Immunofluorescent detection of TSC1 variants was performed as described previously [Mozaffari et al., 2009], using a Leica DM RXA microscope and Image Pro-Plus version 6 image analysis software.

Formatted: Font: Not Italic

Deleted: HEK 293T cells were seeded onto glass coverslips coated with poly-L-lysine (Sigma-Aldrich) and transfected with expression constructs encoding the TSC1 variants. Twenty-four hours after transfection the cells were fixed, permeabilised and incubated with a mouse monoclonal antibody specific for the TSC1 C-terminal myc epitope tag, followed by a Cy2-coupled secondary antibody against mouse immunoglobulins,

Deleted: . Cells were studied

Prediction analysis

To investigate whether the *TSC1* and *TSC2* nucleotide changes might affect RNA splicing, 3 different splice-site prediction programs were used: www.cbs.dtu.dk/services/NetGene2, www.genet.sickkids.on.ca/~ali/splicesitefinder.html, and www.fruitfly.org/seq_tools/splice.html.

To investigate whether the *TSC1* and *TSC2* amino acid substitutions were likely to affect *TSC1-TSC2* structure and function, the Sorting Intolerant From Tolerant (SIFT) algorithm was used [Ng and Henikoff, 2006]. SIFT scores were calculated using multiple sequence alignments of *TSC1* and *TSC2* from 16 different species (human, chimpanzee, maccaca, cow, dog, horse, mouse, rat (*TSC1* only), chicken, zebrafish (*TSC2* only), pufferfish, honey bee (*TSC1* only), fruitfly, mosquito, methylotrophic yeast (*TSC2* only) and fission yeast).

Results

Immunoblot analysis

We compared 152 variants (45 *TSC1* and 107 *TSC2*), including 79 previously untested variants (19 *TSC1* and 60 *TSC2*). Each variant was tested in at least 4 independent transfection experiments. In each experiment, the integrated intensities of

1
2 the bands on the immunoblot corresponding to TSC2, TSC1, total S6K and T389-
3 phosphorylated S6K were determined for each variant, relative to the integrated
4 intensities of the bands for wild-type TSC1-TSC2. Examples of immunoblots of 13
5
6

7
8 TSC1 variants and 15 TSC2 variants are shown in [Supporting Figures S1](#) and [S2](#),
9
10 respectively. The mean values for the TSC2, TSC1 and S6K signals and the mean
11
12 T389/S6K ratios (see below) for all the variants tested are shown in [Figures 2](#), [3](#) and [4](#),
13
14

15 First, to determine whether the transfection efficiencies for the different variant
16
17 constructs were approximately equal, the total S6K signal for each variant was
18
19 compared to the total S6K signal for wild-type TSC1-TSC2. As shown in [Figures 2D](#),
20
21 [3D](#) and [4D](#), the S6K signals were relatively constant for all the variants and controls,
22
23 indicating that the transfection efficiencies were comparable between the different
24

25
26 variants. [For most variants we tested multiple DNA preparations. We did not observe](#)
27
28 [large differences between the replicate DNA preparations, indicating that the quality of](#)
29
30 [the different transfected DNAs was uniform \(Supporting Figure S3\). Furthermore,](#)
31
32 [altering the amount of DNA used for transfection resulted in relatively small changes in](#)
33
34 [the signals detected on the blots, indicating that the assay was robust with respect to the](#)
35
36 [amount of transfected DNA \(Supporting Figure S4\).](#)

37
38 Next, the ratio of the T389-phosphorylated S6K signal to the total S6K signal
39
40 was determined for each variant, relative to wild-type TSC1-TSC2. We referred to this
41
42 as the T389/S6K ratio. The higher the T389/S6K ratio, the higher the estimated activity
43
44 of TORC1, and therefore the lower the activity of the exogenously expressed TSC1 and
45
46 TSC2. The mean T389/S6K ratios for the TSC1 and TSC2 variants are shown in

47
48 [Figures 2C](#), [3C](#) and [4C](#). To determine whether the T389/S6K ratios for the variants were
49
50 significantly increased relative to wild-type TSC1-TSC2, we performed Student's t-
51
52 tests. This was the primary criterium for deciding whether a variant was disease-
53
54
55
56
57
58
59
60

Deleted: 2

Deleted: 3

Deleted: 4

Deleted: 5

Deleted: 6

Deleted: 4

Deleted: 5D

Deleted: 6

Deleted: 4

Deleted: 5

Deleted: 6

causing. We classified the variants with a significantly higher T389/S6K ratio than wild-type TSC1-TSC2 as pathogenic (p value < 0.05). Sixteen TSC1 variants (36%; see Supporting Table S1) and 70 TSC2 variants (65%; see Supporting Tables S2 and S3) were classified as pathogenic. For variants where the T389/S6K ratio was not significantly higher than wild-type TSC1-TSC2 ($p > 0.05$), we compared the T389/S6K ratio to the pathogenic variant that was included in each transfection experiment (TSC2 R611Q for TSC2 variants; TSC1 L117P for TSC1 variants). All the variants that did not have a significantly higher T389/S6K ratio than wild-type TSC1-TSC2, had a significantly lower T389/S6K ratio than the corresponding pathogenic variant, and were therefore considered to be active in our assay. We classified these variants as probably neutral.

In addition to the T389/S6K ratio, we compared the signals of the TSC1 and TSC2 variants to the corresponding signals for the wild-type proteins (Figures 2B, 3A and 4A). Variant signals significantly less than that of the wild-type indicated that the steady state expression of the variant was reduced, either because the variant mRNA was less stable or translated less efficiently than the wild-type mRNA, or that the variant protein was unstable. Therefore, although we could not distinguish between effects on mRNA or protein stability, we classified variants with a significantly reduced signal ($p < 0.05$, paired t-test) as unstable (Supporting Tables S1, S2 and S3). We identified 16 unstable TSC1 variants and 38 unstable TSC2 variants. All of the unstable TSC1 variants had been classified as pathogenic, according to the comparisons between the variant and wild-type T389/S6K ratios. Furthermore, consistent with a previous study [Mozaffari et al., 2009], all the unstable TSC1 variants gave a diffuse cytoplasmic signal as detected by immunofluorescent microscopy, in contrast to wild-type TSC1 and the stable TSC1 variants that all gave a characteristic punctate localisation pattern (data

Deleted: In most cases it was fairly clear whether a variant inhibited S6K T389 phosphorylation or not. However, for a few variants we noticed that there was more inter-experiment variation. Some variants appeared more effective at inhibiting S6K T389 phosphorylation in one experiment compared to the next. An example of this variation is shown in Supplemental Figure 1. Nevertheless, a

Deleted: according to the mean T389/S6K ratios,

Deleted: 16

Deleted: and their wild-type binding partner (TSC1 or TSC2)

Deleted: TSC1-TSC2

Deleted: If the v

Deleted: was

Deleted: protein

Deleted: , then it was evidence that

Deleted: un

Deleted:

Deleted: If the signal for the wild-type binding partner was significantly reduced compared to the corresponding signal for the wild-type complex then it was evidence that the variant was unable to stabilise the TSC1-TSC2 complex. We compared the signal for each variant with the corresponding signal for the wild-type protein (Figures 4B, 5A and 6A). We classified variants with a significantly lower mean signal than the corresponding wild-type protein ($p < 0.05$, paired t-test) as unstable (

Deleted: 9

not shown). Of the unstable TSC2 variants, 35/38 had been defined as pathogenic according to the comparisons of the T389/S6K ratios. In the 3 remaining cases (TSC2 R1159L, TSC2 R1159Q and TSC2 R1772C), the variant inhibited S6K T389-phosphorylation as effectively as wild-type TSC2, despite being detected at lower levels (Figure 4A and C; see Discussion).

Deleted: 6

Deleted: 9

Deleted: 6

Finally, we compared the signals for wild-type TSC1 in the presence of the different TSC2 variants (Figures 3B and 4B), and the signals for wild-type TSC2 in the presence of the different TSC1 variants (Figure 2A). Coexpression of TSC2 stabilises TSC1 [Nellist et al., 1999]. Therefore we classified TSC2 variants that were associated with a significantly reduced TSC1 signal ($p < 0.05$, paired t-test) and TSC1 variants that were associated with a significantly reduced TSC2 signal ($p < 0.05$, paired t-test) as destabilising. Three TSC1 variants, L93R, N198F199delinsI and M224R, were associated with a significant reduction in the TSC2 signal (Figure 2A). In each case we had classified the variant as pathogenic due to a significantly increased T389/S6K ratio compared to wild-type TSC1 (Supporting Table S1). Thirty-eight TSC2 variants were associated with a significant reduction in the TSC1 signal (Figures 3B and 4B). We divided these variants into 2 groups. One group of 31 variants clustered within the N-terminal half of TSC2 (amino acids 98 - 897), while a smaller group of 7 variants clustered close to the C-terminus (amino acids 1525 - 1773). In all 38 cases we had classified the variant as pathogenic due to a significantly increased T389/S6K ratio compared to wild-type TSC1-TSC2 (Supporting Tables S2 and S3).

Deleted: 5

Deleted: 6

Deleted: 4

Deleted: 4

Deleted: 5

Deleted: 6

Prediction Analysis

We investigated the possibility that the nucleotide changes corresponding to variants that did not affect TSC1-TSC2 function in our assay, disrupted *TSC1* or *TSC2*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

splicing. We analysed the *TSC1* and *TSC2* nucleotide changes using 3 different splice-site prediction programs and identified 8 variants (5 *TSC1* and 3 *TSC2*) that were predicted to cause splicing abnormalities (Supporting Tables S1 and S2). In one case (*TSC2* c.1235A>T), this was confirmed by functional assessment of the predicted *TSC2* splice variant, *TSC2* 412del8 (Figure 3, Supporting Figure S2 and Supporting Table S2; [Jansen et al., 2008]).

Deleted: s

Deleted: 3 and 5

Deleted: ,

Next, we investigated whether the functional assessments of the *TSC1* and *TSC2* variants were in agreement with the Sorting Intolerant From Tolerant (SIFT) amino acid substitution prediction method [Ng and Henikoff, 2006]. The SIFT algorithm combines information from the chemical structure of the individual amino acids and the evolutionary conservation of a protein to predict whether specific substitutions can be tolerated by the protein.

Deleted: Overall, there was broad agreement between the SIFT predictions and our functional assessments for both the *TSC1* and *TSC2* variants. Nevertheless, there were sufficient exceptions to indicate that the results of SIFT and similar prediction algorithms should be treated with caution.

SIFT analysis of *TSC1* indicated that the N-terminal (amino acids 1 - 300) and C-terminal (amino acids 700 - 1164) regions were relatively intolerant to amino acid changes [Mozaffari et al., 2009]. All the *TSC1* variants classified as pathogenic according to our functional assessment clustered within the substitution intolerant N-terminal region (Supporting Table S1). SIFT predicted that 18/41 (44%) of the *TSC1* missense changes would not be tolerated. In 36 cases (88%), the SIFT prediction was consistent with the functional assessment. In 5 cases, R190C, R246K, R246T, H732Y and R1097H, SIFT predicted that the substitution would not be tolerated, while the functional assessment indicated that the amino acid changes were probably neutral. In the case of the R246K and R246T substitutions, splice site prediction analysis indicated that the corresponding nucleotide changes (c.737G>A and c.737G>C) were likely to cause splicing errors. Similarly, although the K121R, G305R and G305W substitutions were tolerated by the SIFT analysis and were probably neutral according to the

Deleted: (

Deleted:)

1 functional assessment, splice site analysis predicted that the corresponding nucleotide
 2 changes were splice site mutations. The TSC1 H732Y variant has been identified in
 3 individuals without TSC (<http://www.lovd.nl/TSC1>) and is unlikely to cause TSC,
 4
 5
 6
 7
 8 consistent with the results of our functional assessment (Figure 2, Supporting Figure S1,
 9
 10 and Supporting Table S1). However, this variant is associated with focal cortical
 11 dysplasia type II [Lugnier et al., 2009]. Therefore, the SIFT result may still be accurate,
 12 even though the H732Y substitution is not critical for TSC1 function in our assay. Due
 13 to reduced amino acid sequence conservation at the C-terminus of TSC1, the SIFT
 14 prediction for the TSC1 R1097H substitution was made with a low degree of
 15 confidence, and is therefore not reliable (data not shown).

Deleted: prediction

Deleted: indicated

Deleted: most likely

Deleted: s 2 and 4;

22 SIFT analysis of TSC2 indicated that amino acids 1 - 900 and 1500 - 1807,
 23 corresponding to the TSC1-binding domain and the GAP domain respectively, were
 24 intolerant of amino acid substitutions (Supporting Figure S5). In total, the SIFT
 25 prediction and functional assessment were consistent for 77 TSC2 variants
 26 (80%) (Supporting Tables S2 and S3). SIFT tolerated 42/96 (44%) of the TSC2 amino
 27 acid substitutions subjected to functional testing. Fourteen (31%) of these tolerated
 28 changes were classified as pathogenic according to the functional assessment. In
 29 addition, splice site analysis predicted that the TSC2 c.1118A>C (p.Q373P) variant that
 30 was tolerated by SIFT and classified as neutral according to the functional assessment,
 31 was likely to be a splice site mutation. Of the 54 substitutions that were not tolerated by
 32 SIFT, 5 were classified as neutral according to the functional assessment. For 2 of these,
 33 TSC2 c.1235A>T (p.E412V) and TSC2 c.1255C>T (p.P419S), splice site analysis
 34 predicted that the nucleotide changes would affect splicing.

Deleted: lemen

Deleted: al

Deleted: 2

48 In summary, using a transfection-based immunoblot assay we classified 16/45
 49 TSC1 variants (36%) and 70/107 TSC2 variants (65%) as pathogenic; and 29/45

1
2 TSC1 variants (64%) and 37/107 TSC2 variants (32%) as probably neutral. In 8 cases, 5
3
4 TSC1 and 3 TSC2, the variant was neutral according to the functional assessment, but
5
6 splice site analysis predicted that the corresponding nucleotide change was likely to be a
7
8 pathogenic splice site mutation. Of the 79 previously untested variants, we classified 43
9
10 (54%) as pathogenic, including 5/19 TSC1 (26%) and 38/60 TSC2 variants (63%).
11
12
13
14
15

16 Discussion

17
18 Mutation analysis of individuals with, or suspected of having, a genetic disease
19 facilitates the diagnosis, treatment and genetic counselling of those individuals and their
20 families. However, in some cases it is not possible to determine from the genetic data
21 whether an identified nucleotide change is disease-causing. Functional analysis of
22 predicted protein variants provides an additional method for determining whether
23 specific changes are pathogenic.
24
25
26
27
28
29

30 We have characterised the effects of 152 TSC1 and TSC2 amino acid
31 substitutions and small in-frame insertions/deletions on the TSC1-TSC2 complex.
32
33 Based on our functional assessment we classified 86 (56%) of the changes as
34 pathogenic. In 8 (5%) cases where we did not detect an effect on protein function, the
35
36 corresponding nucleotide change was predicted to cause splicing defects. In one case
37
38 (TSC2 1235A>T), we confirmed that the splicing defect resulted in the production of an
39
40 inactive TSC2 variant [Janssen et al., 2008]. In the remaining 7 cases, additional RNA
41
42 studies are required to confirm the predicted effects on splicing.
43
44
45

Formatted: Font: Italic

46 We tested 45 TSC1 variants, of which 42 were amino acid substitutions and 3
47
48 were in-frame insertion/deletion changes. In 4 cases we analysed multiple changes at
49
50 the same codon. Sixteen variants were detected at significantly reduced levels compared
51
52
53
54
55

1
2 to wild-type TSC1. In each case, TORC1 activity, as estimated from the ratio of T389
3 phosphorylated S6K to total S6K, was increased compared to the wild-type control and
4 we classified these variants as pathogenic. Consistent with previous studies [Nellist et
5 al., 2009, Mozaffari et al., 2009], all the variants that were detected at low levels by
6 immunoblotting mapped to the TSC1 N-terminal region (amino acids 50 - 224) and had
7 a distinct cytoplasmic localisation pattern compared to wild-type TSC1, confirming the
8 importance of this region for TSC1 function, localisation and stability [Hoogveen-
9 Westerveld et al., 2010].

10
11 We tested 104 TSC2 variants, of which 95 were amino acid substitutions, 3 were
12 small in-frame insertions (1 - 3 amino acids) and 6 were in-frame deletions (1 - 26
13 amino acids). In 12 cases we analysed multiple changes at the same codon. Fifty-five
14 changes affected the N-terminal half of the protein (amino acids 1 - 900), and 52
15 affected the C-terminal region (amino acids 901 - 1784). Twenty (36%) of the changes
16 in the N-terminal region were unstable, and 31 (56%) were associated with significantly
17 reduced levels of TSC1, consistent with an important role for the TSC2 N-terminal
18 region in binding and stabilising TSC1 [Li et al., 2004]. Eighteen (35%) of the changes
19 in the C-terminal region were unstable and 7 (13%) were associated with significantly
20 reduced levels of TSC1. The 7 C-terminal variants associated with reduced levels of
21 TSC1 mapped between amino acids 1525 and 1729, suggesting that this region may
22 also play a role in maintaining stable TSC1-TSC2 complexes.

23
24 For 3 TSC2 variants, R1159L, R1159Q and R1772C, the T389/S6K ratio was
25 not significantly different from wild-type TSC1-TSC2, despite the fact that the TSC2
26 signals for these variants were reduced compared to wild-type TSC2. In a previous
27 study we concluded that the R1772C variant was unlikely to be pathogenic because an
28 individual with this variant and TSC had another TSC2 mutation [Nellist et al., 2008].

Deleted: -one

Deleted: 8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Furthermore, individuals with this variant and no signs of TSC have been identified (<http://www.lovd.nl/TSC2>). Therefore, we classified the TSC2 R1772C variant as probably neutral (Supporting Table S3). The R1159L and R1159Q variants were also classified as probably neutral because, despite the reduced signals, they were both able to inhibit S6K T389 phosphorylation as effectively as wild-type TSC1-TSC2. In the TSC2 LOVD, the R1159L variant is classified as unknown, while the R1159Q variant is classified as having no known pathogenicity because it was identified in a TSC patient with another mutation (<http://www.lovd.nl/TSC2>). Nevertheless, *in vivo* it is possible that the reduced stability of the R1159L, R1159Q and R1772C variants renders them less effective at inhibiting TORC1 activity. It would be useful to have additional assays to characterise these variants in more detail.

We compared our functional assessment with the predictions of the SIFT algorithm [Ng and Henikoff, 2006] and with the classifications listed in the TSC1 and TSC2 LOVD (<http://www.lovd.nl/TSC1> and <http://www.lovd.nl/TSC2>) (Supporting Tables S1, S2 and S3). Overall, there was broad agreement (>80%) between the SIFT predictions and our functional assessments for both the TSC1 and TSC2 variants.

Nevertheless, there were sufficient exceptions to indicate that the results of SIFT and similar prediction algorithms should be treated with caution. In general there was also good agreement between the LOVD classifications and our functional assessment.

According to the LOVD classifications, 29 variants had no known pathogenicity or were probably not pathogenic. We classified 27 (93%) of these as probably neutral.

There was strong disagreement for only one TSC1 variant (F216S) and one TSC2 variant (F615S). The TSC1 F216S variant was classified as probably not pathogenic in the TSC1 LOVD because it was identified in a TSC patient and their apparently unaffected parent, but is a pathogenic change according to our functional assessment.

Deleted: TSC1 and TSC2 databases

1
2 Clinical re-evaluation prompted by our findings, showed that the parent has signs of
3 TSC, and therefore the *TSC1* c.647T>C (p.F216S) variant co-segregates with disease in
4 this family. The status of the variant in the *TSC1* LOVD has now been updated to
5 pathogenicity unknown, in line with current LOVD definitions. The *TSC2* F615S
6 substitution was classified as having no known pathogenicity in the *TSC2* LOVD, but is
7 a pathogenic change according to our functional assessment, consistent with our
8 previous studies [Nellist et al., 2001; Nellist et al., 2005]. The *TSC2* c.1844T>C
9 (p.F615S) variant was identified in an individual with TSC and once in a control group
10 of >100 apparently unaffected individuals [Gilbert et al., 1998]. However, as far as we
11 are aware, the variant has not been detected in any other individuals. The status of this
12 variant in the *TSC2* LOVD has now been updated to pathogenicity unknown.
13
14
15
16
17
18
19
20
21
22
23

24 Forty-nine of the variants tested were classified as pathogenic or probably
25 pathogenic in the *TSC1* and *TSC2* LOVD. Forty-one (84%) of these were pathogenic
26 according to our functional assessment. In 5 cases where the functional assessment
27 indicated that the *TSC1* or *TSC2* variant was probably a neutral change, splice site
28 analysis indicated that the corresponding nucleotide change was likely to be a splice site
29 mutation. Therefore there was strong disagreement between the functional assessment
30 and the LOVD classification for only 3 *TSC2* variants, K599M, R951S and L1773I.
31 The *TSC2* K599M substitution is classified as pathogenic in the *TSC2* LOVD because it
32 was reported to be a *de novo* change [Niida et al., 1999] that reduced the *TSC2*-
33 dependent inhibition of 4E-BP1 phosphorylation *in vitro* [Tee et al., 2002]. However,
34 consistent with our previous studies [Nellist et al., 2001; Nellist et al., 2005], in our
35 assay, the K599M substitution did not affect *TSC1* or *TSC2* stability and inhibited S6K
36 T389 phosphorylation as effectively as wild-type *TSC2*. The status of this variant in the
37 *TSC2* LOVD has now been changed to pathogenicity unknown as it is not clear why
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 there is a discrepancy between the different reports. The TSC2 R951S substitution was
3
4 classified as probably pathogenic in the *TSC2* LOVD, but is probably neutral according
5
6 to our functional assessment. No additional family data was available for this variant
7
8 and therefore according to the current LOVD classification criteria, the variant should
9
10 be classified as pathogenicity unknown. Codon 951 is encoded by the alternatively
11
12 spliced exon 25 of the *TSC2* gene [Xu et al., 1995]. Very few pathogenic changes have
13
14 been identified in this exon (<http://www.lovd.nl/TSC2>), and complete removal of this
15
16 exon did not affect TSC2 function in our assay (M. Wentink, M. Nellist, unpublished
17
18 observations). Finally, the TSC2 L1773I variant was classified as probably pathogenic
19
20 in the *TSC2* LOVD, but is probably neutral according to our functional assessment.
21
22 Although the *TSC2* c.5386C>A (p.L1773I) is listed as a *de novo* change, there is no
23
24 record that paternity testing was performed, and it is possible that the *TSC2* c.5386C>A
25
26 (p.L1773I) variant is a rare neutral variant.
27

28 Although in most cases it was clear whether a variant inhibited S6K T389
29 phosphorylation or not, for a few variants we noticed that there was more inter-
30 experiment variation. Some variants appeared more effective at inhibiting S6K T389
31 phosphorylation in one experiment compared to the next. An example of this variation
32 is shown in Supporting Figure S6. Furthermore, in some cases, the signal of the variant
33 itself, or its binding partner, was quite variable, even though the transfection efficiency,
34 as assessed by the S6K signal, was constant. For example, the mean signals for TSC2 in
35 the presence of the TSC1 I76N and L93R variants are approximately equal (Figure 2A;
36 Supporting Table S1). However, because the TSC2 signal showed more inter-
37 experiment variation in the presence of the I76N variant, it was not significantly
38 different from the wild-type signal, while the TSC2 signal in the presence of the L93R
39 variant was significantly reduced compared to the wild-type. For this reason, it is
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

possible that our assay missed some variants that are slightly less active or stable than wild-type TSC1 or TSC2. Therefore, although we could clearly distinguish variants that were less active than wild-type TSC1 and TSC2, it was more difficult to be certain that variants that were indistinguishable from wild-type in our assay were neutral variants, and not pathogenic. Nevertheless, we classified 29 TSC1 and 37 TSC2 variants as probably neutral because they were able to inhibit S6K T389 phosphorylation as effectively as wild-type TSC1-TSC2 in our assay. In the majority of cases these variants are most likely to be rare, neutral variants that do not cause TSC. However, we could not exclude the possibility that some variants have sufficient activity in our over-expression system to inhibit TORC1, while *in vivo* they may be inactive or unstable. Furthermore, we did not investigate any other TORC1-dependent or -independent effects of TSC1 or TSC2. Some variants might affect other TSC1-TSC2 functions than the TSC1-TSC2 interaction or TORC1 signalling to S6K. Additional analysis of the variants classified here as probably neutral is necessary to determine whether these variants affect other TSC1-TSC2 functions.

Despite these notes of caution, we conclude that our functional assessment has provided important insight into whether specific TSC1 and TSC2 variants are pathogenic. In summary, we classified 152 different TSC1 and TSC2 variants using a transfection-based immunoblot assay that distinguished pathogenic TSC1 and TSC2 variants from probable neutral variants according to whether there was increased S6K-T389 phosphorylation. Based on this functional assessment, 86 variants were classified as pathogenic and 67 as probably neutral, providing useful information for genetic counselling in the individuals carrying these variants.

Deleted: ¶
A

Deleted: W

Deleted: In 3 cases, TSC2 R1159L, R1159Q and R1772C, the T389/S6K ratio was not significantly different from wild-type TSC1-TSC2, despite the fact that the TSC2 signals for these variants were reduced compared to wild-type TSC2. In a previous study we concluded that the R1772C variant was unlikely to be pathogenic because an individual with this variant and TSC had another TSC2 mutation [Nellist et al., 2008]. Furthermore, individuals with this variant and no signs of TSC have been identified (<http://www.lovd.nl/TSC2>). Therefore, we classified the TSC2 R1772C variant as probably neutral (Table 3). The antiserum used to detect the TSC2 variants binds epitopes encoded by the last exon of TSC2, which includes codon 1772 (M. Wentink, M. Nellist; unpublished results) and it is possible that the R1772C substitution reduces the affinity of the antiserum for TSC2, resulting in a lower immunoblot signal. The R1159L and R1159Q variants were also classified as probably neutral because, despite the reduced signals, they were both able to inhibit S6K T389 phosphorylation as effectively as wild-type TSC1-TSC2. In the LOVD TSC2 database, the R1159L variant is classified as unknown, while the R1159Q variant is classified as having no known pathogenicity because it was identified in a TSC patient with another mutation (<http://www.lovd.nl/TSC2>). Nevertheless, *in vivo* it is possible that the reduced stability of the R1159L and R1159Q variants renders them unable to effectively inhibit TORC1 activity and we could therefore not completely exclude the possibility that these variants are pathogenic. For this reason it would be useful to have additional assays to characterise these variants in more detail.¶

Deleted: i

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments

Financial support was provided by the U.S. Department of Defense
Congressionally-Directed Medical Research Program (grant #TS060052), the Michelle
Foundation and the Tuberous Sclerosis Alliance. The authors report no conflicts of
interest.

For Peer Review

References

Au K-S, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless

JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY,

Whittemore VH, King TM, Northrup H. 2007. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.

Genet Med 9:88-100.

Coevoets R, Arican S, Hoogeveen-Westerveld M, Simons E, van den Ouweland A,

Halley D, Nellist M 2009 A reliable cell-based assay for testing unclassified *TSC2* gene variants. Eur J Hum Genet 17:301-310.

Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP,

Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. 2001.

Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of *TSC2*, compared with *TSC1*, disease in multiple organs. Am J Hum Genet 68:64-80.

Daumke O, Weyand M, Chakrabarti PP, Vetter IR, Wittinghofer A. 2004. The GTPase-activating protein Rap1GAP uses a catalytic asparagine. Nature 429:197-201.

European Chromosome 16 Tuberous Sclerosis Consortium. 1993 Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315.

Deleted: Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. 2003. Human bladder tumors with 2-hit mutations of tumor suppressor gene *TSC1* and decreased expression of p27. J. Urol. 170:601-604.

Deleted: Benit P, Kara-Mostefa A, Hadj-Rabia S, Munnich A, Bonnefont JP. 1999. Protein truncation test for screening hamartin gene mutations and report of new disease-causing mutations. Hum Mutat 14:428-432.
Choi JE, Chae JH, Hwang YS, Kim KJ. 2006. Mutational analysis of *TSC1* and *TSC2* in Korean patients with tuberous sclerosis complex. Brain Dev 28:440-446.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Gilbert JR, Guy V, Kumar A, Wolpert C, Kandt R, Aylesworth A, Roses AD, Pericak-Vance MA. 1998. Mutation and polymorphism analysis in the tuberous sclerosis 2 (*TSC2*) gene. *Neurogenetics* 1:267-272.

Gomez MG, Sampson JR, Holets-Whittemore V, eds. 1999 The tuberous sclerosis complex. 3rd edn. *Developmental Perspectives in Psychiatry*, Oxford University Press, New York and Oxford.

Hoogeveen-Westerveld M, Exalto C, Maat-Kievit A, van den Ouweland A, Halley D, Nellist M. 2010. Analysis of *TSC1* truncations defines regions involved in *TSC1* stability, aggregation and interaction. *Biochim Biophys Acta* 1802:774-781.

Deleted: Hodges AK, Li S, Maynard J, Parry L, Braverman R, Cheadle JP, DeClue JE, Sampson JR. 2001. Pathological mutations in *TSC1* and *TSC2* disrupt the interaction between hamartin and tuberin. *Hum Mol Genet* 10:2899-2905.¶

Inoki K, Li Y, Zhu T, Wu J, Guan K-L. 2002. *TSC2* is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nat Cell Biol* 4:648-657.

Deleted: Huang J, Dibble CC, Matsuzaki M, Manning BD. 2008. The *TSC1-TSC2* complex is required for proper activation of mTOR complex 2. *Mol Cell Biol* 28:4104-4115.¶
Hung CC, Su YN, Chien SC, Liou HH, Chen CC, Chen PC, Hsieh CJ, Chen CP, Lee WT, Lin WL, Lee CN. 2006. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. *BMC Med Genet* 7:72.¶

Inoki K, Guan K-L. 2009. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. *Hum Mol Genet* 18:R94-R100.

Jansen FE, Braams O, Vincken KL, Algra A, Anbeek P, Jennekens-Schinkel A, Halley D, Zonnenberg BA, van den Ouweland A, van Huffelen AC, van Nieuwenhuizen O, Nellist M. 2008. Overlapping neurologic and cognitive phenotypes in patients with *TSC1* or *TSC2* mutations. *Neurology* 70:908-915.

Deleted: Jansen AC, Sancak O, D'Agostino MD, Badhwar A, Roberts P, Gobbi G, Wilkinson R, Melanson D, Tampieri D, Koenekoop R, Gans M, Maat-Kievit A, Goedbloed M, van den Ouweland AMW, Nellist M, Pandolfo M, McQueen M, Sims K, Thiele EA, Dubeau F, Andermann F, Kwiatkowski DJ, Halley DJJ, Andermann E. 2006. Unusually mild tuberous sclerosis phenotype is associated with *TSC2* R905Q mutation. *Ann Neurol*. 60:528-539.¶

Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, Sampson JR, Cheadle JP. 1999. Comprehensive mutation analysis of *TSC1* and *TSC2*,

1
2 and phenotypic correlations in 150 families with tuberous sclerosis. *Am J Hum Genet*
3
4 64:1305-1315.
5
6

7
8 Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N,
9
10 Onda H. 2001. A mouse model of TSC1 reveals sex-dependent lethality from liver
11
12 hemangiomas, and up-regulation of p70S6 kinase activity in *Tsc1* null cells. *Hum Mol*
13
14 *Genet* 11:525-534.
15
16

Deleted: Khare L, Strizheva GD, Bailey JN, Au K-S, Northrup H, Smith M, Smalley SL, Henske EP. 2001. A novel missense mutation in the GTPase activating protein homology region of *TSC2* in two large families with tuberous sclerosis complex. *J Med Genet* 38:347-349.¶

17
18 Li Y, Corradetti MN, Inoki K, Guan J-L. 2003. TSC2: filling the GAP in the mTOR
19
20 signaling pathway. *Trends Biochem Sci* 28:573-576.
21
22

23
24 Li Y, Inoki K, Guan K-L. 2004. Biochemical and functional characterization of small
25
26 GTPase Rheb and TSC2 GAP activity. *Mol Cell Biol* 24:7965-7975.
27
28

29
30 Lugnier C, Majores M, Fassunke J, Pernhorst K, Niehusmann P, Simon M, Nellist M,
31
32 Schoch S, Becker A. 2009. Hamartin variants that are frequent in focal dysplasias and
33
34 cortical tubers have reduced tuberin binding and aberrant subcellular distribution in
35
36 vitro. *J Neuropathol Exp Neurol* 68:1136-1146.
37
38

39
40 Mozaffari M, Hoogeveen-Westerveld M, Kwiatkowski D, Sampson J, Ekong R, Povey
41
42 S, den Dunnen JT, van den Ouweland A, Halley D, Nellist M. 2009. Identification of a
43
44 region required for TSC1 stability by functional analysis of *TSC1* missense mutations
45
46 found in individuals with tuberous sclerosis complex. *BMC Med Genet* 10:88.
47
48
49
50
51
52
53
54
55

Deleted: Mayer K, Goedbloed M, van Zijl K, Nellist M, Rott HD. 2004. Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis. *J Med Genet* 41:64.¶

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Nellist M, van Slegtenhorst MA, Goedbloed M, van den Ouweland AMW, Halley DJJ, van der Sluijs P. 1999. Characterization of the cytosolic tuberlin-hamartin complex: tuberlin is a cytosolic chaperone for hamartin. *J Biol Chem* 274:35647-35652.

Nellist M, Verhaaf B, Goedbloed MA, Reuser AJJ, van den Ouweland AMW, Halley DJJ. 2001. *TSC2* missense mutations inhibit tuberlin phosphorylation and prevent formation of the tuberlin-hamartin complex. *Hum Molec Genet* 10:2889-2898.

Nellist M, Sancak O, Goedbloed MA, Rohe C, van Netten D, Mayer K, Tucker-Williams A., van den Ouweland AMW, Halley DJJ. 2005. Distinct effects of single amino acid changes to tuberlin on the function of the tuberlin-hamartin complex. *Eur J Hum Genet* 13:59-68.

Nellist M, Sancak O, Goedbloed M, Adriaans A, Wessels M, Maat-Kievit A, Baars M, Dommering C, van den Ouweland A, Halley D. 2008. Functional characterisation of the *TSC1-TSC2* complex to assess multiple *TSC2* variants identified in single families affected by tuberous sclerosis complex. *BMC Med Genet* 9:10.

Nellist M, van den Heuvel D, Schlupe D, Exalto C, Goedbloed M, Maat-Kievit A, van Essen T, van Spaendonck-Zwarts K, Jansen F, Helderman P, Bartalini G, Vierimaa O, Penttinen M, van den Ende J, van den Ouweland A, Halley D. 2009. Missense mutations to the *TSC1* gene cause tuberous sclerosis complex. *Eur J Hum Genet* 17:319-328.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ng PC, Henikoff S. 2006. Predicting the effects of amino acid substitutions on protein function. *Ann Rev Genomics Hum Genet* 7:61-80.

Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL, Sims K, Ramesh V, Ozelius L. 1999. Analysis of both *TSC1* and *TSC2* for germline mutations in 126 unrelated patients with tuberous sclerosis. *Hum Mutat* 14:412-422.

Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. 2005 Mutational analysis of the *TSC1* and *TSC2* genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. *Eur J Hum Genet* 13:731-741.

van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Wolfe J, Povey S, Osborne J, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JBM, Ward S, Green AJ, Yates JRW, Short MP, Haines JH, Jozwiak S, Kwiatkowska J, Henske EP, Kwiatkowski DJ. 1997. Identification of the tuberous sclerosis gene *TSC1* on chromosome 9q34. *Science* 277:805-808.

van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P. 1998. Interaction between hamartin and tuberin, the *TSC1* and *TSC2* gene products. *Hum Mol Genet* 7:1053-1057.

Deleted: O'Connor SE, Kwiatkowski DJ, Roberts PS, Wollmann RL, Huttenlocher PR. 2003. A family with seizures and minor features of tuberous sclerosis and a novel *TSC2* mutation. *Neurology* 61:409-412.¶
¶
Qin W, Kozlowski P, Taillon BE, Bouffard P, Holmes AJ, Janne P, Camposano S, Thiele E, Franz D, Kwiatkowski DJ. 2010a. Ultra deep sequencing detects a low rate of mosaic mutations in Tuberous Sclerosis Complex. *Hum Genet* 127:573-582.¶
¶
Qin W, Chan JA, Vinters HV, Mathern GW, Franz DN, Taillon BE, Bouffard P, Kwiatkowski DJ. 2010b. Analysis of TSC cortical tubers by deep sequencing of *TSC1*, *TSC2* and *KRAS* demonstrates that small second-hit mutations in these genes are rare events. *Brain Pathol* doi:10.1111/j.1750-3639.2010.00416.x.¶
¶
Ramantani G, Niggemann P, Hahn G, Nake A, Fahsold R, Lee-Kirsch MA. 2008. Unusual radiological presentation of tuberous sclerosis complex with leptomeningeal angiomatosis associated with a hypomorphic mutation in the *TSC2* gene. *J Child Neurol* 24:333-337.¶
¶
Rendtorff ND, Bjerregaard B, Frodin M, Kjaergaard S, Hove H, Skovby F, Brondum-Nielsen K, Schwartz M. 2005. Analysis of 65 tuberous sclerosis complex (TSC) patients by *TSC2* DGGE, *TSC1/TSC2* MLPA, and *TSC1* long-range PCR sequencing, and report of 28 novel mutations. *Hum Mutat* 26:374-383.¶
¶

1
2
3
4 Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. 2002.
5
6 Tuberos sclerosis complex-1 and -2 gene products function together to inhibit
7
8 mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl
9
10 Acad Sci USA 99:13571-13576.
11

12
13
14 de Vries P, Howe CJ. 2007. The tuberous sclerosis complex proteins - a GRIPP on
15
16 cognition and neurodevelopment. Trends Mol Med 13:319-326.
17

18
19
20 Xu L, Sterner C, Maheshwar MM, Wilson PJ, Nellist M, Short PM, Haines JL,
21
22 Sampson JR, Ramesh V. 1995. Alternative splicing of the tuberous sclerosis 2 (*TSC2*)
23
24 gene in human and mouse tissues. Genomics 27:475-480.
25

26
27
28 Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F,
29
30 Carpenter CL, Kwiatkowski DJ. 2003. Loss of *Tsc1/Tsc2* activates mTOR and disrupts
31
32 PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223-1233.
33

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: ¶
Zhang H, Nanba E, Yamamoto T,
Ninomiya H, Ohno K, Mizuguchi M,
Takeshita K. 1999. Mutational analysis of
TSC1 and *TSC2* genes in Japanese
patients with tuberous sclerosis complex.
J Hum Genet 44:391-396.¶

Titles and legends to figures

Figure 1: Overview of the TSC1 and TSC2 variants analysed as part of this study.

Amino acid variants are numbered as originally described [van Slechtenhorst et al., 1997; European Chromosome 16 Tuberous Sclerosis Consortium, 1993] ([Genbank AF013168.1; GI: 2331280 \(TSC1\) and X75621; GI:450351 \(TSC2\)](#)) and according to the amino acid sequences encoded by the expression constructs used in this study. [The initiation codon is codon 1.](#)

(A) TSC1 variants. The positions of the TSC1 variants analysed as part of this study are indicated relative to the coding exons (3 - 23) of the *TSC1* gene.

(B) Variants mapping to the N-terminal half of TSC2 (amino acids 1 - 900). The positions of the variants are indicated relative to exons 1 - 23 of the *TSC2* gene.

(C) Variants mapping to the C-terminal half of TSC2 (amino acids 901 - 1784). The positions of the variants are indicated relative to exons 23 - 41 of the *TSC2* gene. The alternatively spliced exons 25 and 31 are shown in grey and the position of the GAP domain, corresponding to exon 37, is shown in black. The amino acids encoded by exon 31 were not present in the TSC2 expression constructs used in this study.

Figure 2: Functional assessment of the TSC1 variants. The signals for TSC2, TSC1, total S6K (S6K) and T389-phosphorylated S6K (T389) were determined per variant, relative to the wild-type control (TSC1) in at least 4 independent transfection experiments. The mean signals are shown for each variant. Error bars represent the standard error of the mean; variants that were significantly different from the wild-type control (TSC1) are indicated with an asterisk. The signals from cells expressing exogenous TSC2 and S6K only, and no exogenous TSC1, are also shown (TSC2).

Deleted: ¶

Figure 2: Immunoblot analysis of TSC1 variants. Cells were transfected with expression constructs encoding TSC2, S6K and wild-type TSC1 (TSC1/TSC2/S6K), TSC2, S6K and the pathogenic L117P variant (L117P), TSC2, S6K and the TSC1 variants, TSC2 and S6K only (TSC2/S6K), TSC1 and S6K only (TSC1/S6K) or with an empty vector (control) and analysed by immunoblotting. ¶

(A) Immunoblot showing signals for wild-type TSC2 (TSC2), wild-type TSC1 and the TSC1 variants (TSC1), total S6K (S6K) and T389-phosphorylated S6K (T389).¶

(B) Quantification of the TSC2 signals shown in (A), relative to the wild-type control (TSC1/TSC2/S6K).¶

(C) Quantification of the TSC1 signals shown in (A), relative to the wild-type control (TSC1/TSC2/S6K).¶

(D) Quantification of the total S6K signals shown in (A), relative to the wild-type control (TSC1/TSC2/S6K).¶

(E) Ratio of T389-phosphorylated S6K to total S6K in the presence of the TSC1 variants. The ratio of the signal for T389 phosphorylated S6K (T389) to the total S6K protein (S6K) was determined relative to the wild-type control (TSC1/TSC2/S6K; T389/S6K ratio = 1) for each variant shown in (A).¶

¶ **Figure 3:** Immunoblot analysis of TSC2 variants. Cells were transfected with expression constructs encoding TSC1, S6K and wild-type TSC2 (TSC2), TSC1, S6K and the pathogenic R611Q variant (R611Q), TSC1, S6K and the TSC2 variants, or with an empty vector (control), and analysed by immunoblotting. ¶

(A) Immunoblot showing signals for wild-type TSC2 and the TSC2 variants (TSC2), wild-type TSC1 (TSC1), total S6K (S6K) and T389-phosphorylated S6K (T389).¶

(B) Quantification of the TSC2 signals shown in (A), relative to the wild-type control (TSC2).¶

(C) Quantification of the TSC1 signals shown in (A), relative to the wild-type control (TSC2).¶

(D) Quantification of the total S6K signals shown in (A), relative to the wild-type control (TSC2).¶

(E) Ratio of T389-phosphorylated S6K to total S6K in the presence of the TSC2 variants. The ratio of the signal for T389 phosphorylated S6K (T389) to the total S6K protein (S6K) was determined relative to the wild-type control (TSC2; T389/S6K ratio = 1) for each variant shown in (A).¶

Deleted: 4.:

1
2 (A) Mean TSC2 signals in the presence of the TSC1 variants, relative to wild-type

3
4 TSC1-TSC2 (TSC1; TSC2 signal = 1).

5
6 (B) Mean signals for the TSC1 variants, relative to wild-type TSC1 (TSC1; TSC1 signal

7
8 =1).

9
10 (C) Mean T389/S6K ratios for the TSC1 variants, relative to wild-type TSC1-TSC2

11
12 (TSC1; T389/S6K ratio = 1).

13
14 (D) Mean total S6K signals in the presence of the TSC1 variants, relative to wild-type

15
16 TSC1-TSC2 (TSC1; S6K signal = 1).

17
18
19
20 **Figure 3:** Functional assessment of the TSC2 variants mapping to the N-terminal half

Deleted: 5.:

21
22 of TSC2 (amino acids 1 - 900). The signals for TSC2, TSC1, total S6K (S6K) and
23
24 T389-phosphorylated S6K (T389) were determined per variant, relative to the wild-type
25
26 control (TSC2) in at least 4 independent transfection experiments. The mean signals are
27
28 shown for each variant. Error bars represent the standard error of the mean; variants that
29
30 were significantly different from the wild-type control (TSC2) are indicated with an
31
32 asterisk.

33
34 (A) Mean signals for the TSC2 variants, relative to wild-type TSC1-TSC2 (TSC2;

35
36 TSC2 signal =1).

37
38 (B) Mean TSC1 signals in the presence of the TSC2 variants, relative to wild-type

39
40 TSC1-TSC2 (TSC2; TSC1 signal = 1).

41
42 (C) Mean T389/S6K ratios for the TSC2 variants, relative to wild-type TSC1-TSC2

43
44 (TSC2; T389/S6K ratio = 1).

45
46 (D) Mean total S6K signals in the presence of the TSC2 variants, relative to wild-type

47
48 TSC1-TSC2 (TSC2; S6K signal = 1).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4: Functional assessment of the TSC2 variants mapping to the C-terminal half of TSC2 (amino acids 901 - 1784). The signals for TSC2, TSC1, total S6K (S6K) and T389-phosphorylated S6K (T389) were determined per variant, relative to the wild-type control (TSC2) in at least 4 independent transfection experiments. The mean signals are shown for each variant. Error bars represent the standard error of the mean; variants that were significantly different from the wild-type control (TSC2) are indicated with an asterisk.

Deleted: 6.:

Formatted: Font: Bold


(A) Mean signals for the TSC2 variants, relative to wild-type TSC2 (TSC2; TSC2 signal = 1).

(B) Mean TSC1 signals in the presence of the TSC2 variants, relative to wild-type TSC1-TSC2 (TSC2; TSC1 signal = 1).

(C) Mean T389/S6K ratios for the TSC2 variants, relative to wild-type TSC1-TSC2 (TSC2; T389/S6K ratio = 1).


(D) Mean total S6K signals in the presence of the TSC2 variants, relative to wild-type TSC1-TSC2 (TSC2; S6K signal = 1).

Figure 1



168x151mm (300 x 300 DPI)


Figure 2



160x217mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2



159x213mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3







Figure 4



171x227mm (300 x 300 DPI)

Supporting Figure S1:



Immunoblot analysis of TSC1 variants. Cells were transfected with expression constructs encoding TSC2, S6K and wild-type TSC1 (TSC1/TSC2/S6K), TSC2, S6K and the pathogenic L117P variant (L117P), TSC2, S6K and the TSC1 variants, TSC2 and S6K only (TSC2/S6K), TSC1 and S6K only (TSC1/S6K) or with an empty vector (control) and analysed by immunoblotting.

(A) Immunoblot showing signals for wild-type TSC2 (TSC2), wild-type TSC1 and the TSC1 variants (TSC1), total S6K (S6K) and T389-phosphorylated S6K (T389).


1
2
3 (B) Quantification of the TSC2 signals shown in (A), relative to the wild-type control
4
5 (TSC1/TSC2/S6K).
6

7
8 (C) Quantification of the TSC1 signals shown in (A), relative to the wild-type control
9
10 (TSC1/TSC2/S6K).
11

12
13 (D) Quantification of the total S6K signals shown in (A), relative to the wild-type
14
15 control (TSC1/TSC2/S6K).
16

17 (E) Ratio of T389-phosphorylated S6K to total S6K in the presence of the TSC1
18
19 variants. The ratio of the signal for T389 phosphorylated S6K (T389) to the total S6K
20
21 protein (S6K) was determined relative to the wild-type control (TSC1/TSC2/S6K;
22
23 T389/S6K ratio = 1) for each variant shown in (A).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supporting Figure S2:



1
2
3 Immunoblot analysis of TSC2 variants. Cells were transfected with expression
4
5 constructs encoding TSC1, S6K and wild-type TSC2 (TSC2), TSC1, S6K and the
6
7 pathogenic R611Q variant (R611Q), TSC1, S6K and the TSC2 variants, or with an
8
9 empty vector (control), and analysed by immunoblotting.
10
11

12 (A) Immunoblot showing signals for wild-type TSC2 and the TSC2 variants (TSC2),
13
14 wild-type TSC1 (TSC1), total S6K (S6K) and T389-phosphorylated S6K (T389).
15
16


17 (B) Quantification of the TSC2 signals shown in (A), relative to the wild-type control
18
19 (TSC2).
20
21

22 (C) Quantification of the TSC1 signals shown in (A), relative to the wild-type control
23
24 (TSC2).
25
26

27 (D) Quantification of the total S6K signals shown in (A), relative to the wild-type
28
29 control (TSC2).
30
31

32 (E) Ratio of T389-phosphorylated S6K to total S6K in the presence of the TSC2
33
34 variants. The ratio of the signal for T389 phosphorylated S6K (T389) to the total S6K
35
36 protein (S6K) was determined relative to the wild-type control (TSC2; T389/S6K ratio
37
38 = 1) for each variant shown in (A).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supporting Figure S3:



Immunoblot analysis of different DNA preparations of the TSC2 R1200W, A889V, V334G, V334A and R57H variants. Cells were transfected with expression constructs encoding TSC1, S6K and wild-type TSC2 (TSC2), TSC1, S6K and the pathogenic R611Q variant (R611Q), TSC1, S6K and the TSC2 variants, or with an empty vector (control), and analysed by immunoblotting. Three different preparations of the TSC2 R1200W and A889V variant expression constructs and 2 different preparations of the V334G, V334A and R57H variant constructs were tested.

1
2
3 (A) Immunoblot showing signals for wild-type TSC2 and the TSC2 variants (TSC2),
4 wild-type TSC1 (TSC1), total S6K (S6K) and T389-phosphorylated S6K (T389).
5
6


7 (B) Quantification of the TSC2 signals shown in (A). Mean signals for the different
8 variants are shown relative to the wild-type control (TSC2). Error bars indicate the
9 standard error of the mean.
10
11

12 (C) Quantification of the TSC1 signals shown in (A), relative to the wild-type control
13 (TSC2).
14
15

16 (D) Quantification of the total S6K signals shown in (A), relative to the wild-type
17 control (TSC2).
18
19

20 (E) Ratio of T389-phosphorylated S6K to total S6K in the presence of the TSC2
21 variants. The ratio of the signal for T389 phosphorylated S6K (T389) to the total S6K
22 protein (S6K) was determined relative to the wild-type control (TSC2; T389/S6K ratio
23 = 1) for each variant shown in (A).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supporting Figure S4:




Immunoblot analysis of wild-type TSC2 and the TSC2 R1200W and R611Q variants.

Cells were transfected with expression constructs encoding TSC1 (0.4 μg), S6K (0.1 μg) and the indicated amounts of the TSC2 expression constructs, and analysed by immunoblotting. Control cells (control) were transfected with 0.7 μg empty vector. The effects of the TSC2 R1200W and R611Q variants on S6K T389 phosphorylation are clearly distinguishable from wild-type TSC2 across the whole range of transfected TSC2 expression construct DNA (0.05 - 0.4 μg).


Supporting Figure S5:

TSC2 SIFT analysis



SIFT analysis of TSC2. The TSC2 amino acid sequence from the *TSC2* LOVD was analysed using the SIFT algorithm. The number of tolerated and not tolerated substitutions was determined for each amino acid residue. In the figure each amino acid position is represented by a box. Solid green boxes represent positions that are completely tolerant (all substitutions possible, according to SIFT); open green boxes represent positions where 1 or 2 substitutions are not tolerated. Solid red boxes represent intolerant positions (no substitutions tolerated); open red boxes represent positions where 3 or fewer substitutions are tolerated. Empty boxes represent positions where between 3 and 17 substitutions are tolerated.

Supporting Figure S6:



Immunoblot analysis of the TSC2 105insALL and V560M variants. Cells were transfected with expression constructs encoding TSC1, S6K and wild-type TSC2 (TSC2) or the TSC2 105insALL, V560M or R611Q variants, and analysed by immunoblotting in 2 separate experiments, as shown in A and B. Note the apparent increase in the T389-phosphorylated S6K signal for the V560M variant in B compared to A.

Supporting Table S1:

TSCI variants. *TSCI* nucleotide changes and exon numbers are given according to the *TSCI* LOVD (<http://www.lovd.nl/TSCI>). Nucleotide numbering reflects the *TSCI* cDNA numbering (Genbank AF013168.1; GI: 2331280) with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). Amino acid changes are numbered accordingly; the initiation codon is codon 1. Nucleotide changes predicted to cause splicing defects are marked with an asterisk.

Amino acid substitutions predicted by SIFT to be tolerated (T) or not tolerated (NT) are indicated. Previously untested variants are indicated in bold. Links to the original references describing the different variants can be accessed via the *TSCI* LOVD. Variants not previously listed in the *TSCI* LOVD are indicated as 'not listed'.

Exon	Variant	SIFT prediction	LOVD classification	Functional assessment
4	c.149T>C (p.L50P)	NT	unknown	unstable, pathogenic
4	c.153A>C (p.E51D)	T	probably no pathogenicity	probably neutral
4	c.182T>C (p.L61P)	NT	probably pathogenic	unstable, pathogenic
5	c.215T>C (p.L72P)	NT	probably pathogenic	unstable, pathogenic

5	c.227T>A (p.I76N)	NT	unknown	unstable, pathogenic
5	c.245A>C (p.K82T)	T	unknown	probably neutral
5	c.250G>A (p.A84T)	T	probably no pathogenicity	probably neutral
5	c.278T>G (p.L93R)	NT	probably pathogenic	unstable, destabilising, pathogenic
5	c.346T>G (p.L116V)	T	not listed	probably neutral
5	c.350T>C (p.L117P)	NT	probably pathogenic	unstable, pathogenic
5	c.362A>G* (p.K121R)	T	unknown	probably neutral (predicted splice mutation)
6	c.381_383delTGT* (p.128delV)	-	unknown	unstable, pathogenic
6	c.397G>T (p.V133F)	NT	unknown	unstable, pathogenic
7	c.539T>C (p.L180P)	NT	probably pathogenic	unstable, pathogenic
7	c.568C>T (p.R190C)	NT	no known pathogenicity	probably neutral
7	c.569G>C	NT	unknown	unstable, pathogenic

	(p.R190P)			
7	c.572T>A (p.L191H)	NT	probably pathogenic	unstable, pathogenic
7	c.572T>G (p.L191R)	NT	unknown	unstable, pathogenic
7	c.593_595delACT (p.N198F199delinsI)	-	probably pathogenic	unstable, destabilising, pathogenic
7	c.602_604delCCT (p.S201del)	-	unknown	unstable, pathogenic
7	c.647T>C (p.F216S)	NT	probably no pathogenicity; updated to unknown	unstable, pathogenic
8	c.671T>G (p.M224R)	NT	probably pathogenic	unstable, destabilising, pathogenic
8	c.737G>A* (p.R246K)	NT	probably pathogenic	probably neutral (predicted splice mutation)
8	c.737G>C* (p.R246T)	NT	probably pathogenic	probably neutral (predicted splice mutation)
9	c.853T>G (p.F285V)	T	not listed	probably neutral

9	c.913G>A* (p.G305R)	T	probably pathogenic	probably neutral (predicted splice mutation)
9	c.913G>T* p.G305W	T	probably pathogenic	probably neutral (predicted splice mutation)
10	c.1001C>T p.S334L	T	probably no pathogenicity	probably neutral
12	c.1250C>T (p.T417I)	T	no known pathogenicity	probably neutral
14	c.1433A>G* (p.E478G)	T	unknown	probably neutral
14	c.1433A>G* (p.E478GinsGN)	-	unknown	probably neutral
15	c.1460C>G (p.S487C)	T	not listed	probably neutral
15	c.1526G>A (p.R509Q)	T	probably no pathogenicity	probably neutral
15	c.1648C>G (p.Q550E)	T	unknown	probably neutral
15	c.1760A>G (p.K587R)	T	no known pathogenicity	probably neutral
15	c.1849C>G (p.H617D)	T	not listed	probably neutral
15	c.1974C>G	T	probably no	probably neutral

	(p.D658E)		pathogenicity	
15	c.1976C>T (p.A659V)	T	probably no pathogenicity	probably neutral
17	c.2194C>T (p.H732Y)	NT	no known pathogenicity	probably neutral
19	c.2420T>C (p.I807T)	T	unknown	probably neutral
21	c.2653C>T (p.R885W)	T	unknown	probably neutral
21	c.2696C>G (p.T899S)	T	unknown	probably neutral
23	c.3103G>A (p.G1035S)	T	no known pathogenicity	probably neutral
23	c.3184C>T (p.R1062W)	T	unknown	probably neutral
23	c.3290G>A (p.R1097H)	NT	probably no pathogenicity	probably neutral

Supporting Table S2:

TSC2 variants (amino acids 1 - 900). *TSC2* nucleotide changes and exon numbers are given according to the *TSC2* LOVD (<http://www.lovd.nl/TSC2>). Nucleotide numbering reflects the *TSC2* cDNA numbering (Genbank X75621; GI:450351) with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). Amino acid changes were numbered accordingly; the initiation codon is codon 1. Nucleotide changes predicted to cause splicing defects are marked with an asterisk.

Amino acid substitutions predicted by SIFT to be tolerated (T) or not tolerated (NT) are indicated. Links to the original references describing the different variants can be accessed via the *TSC2* LOVD. Variants not previously listed in the *TSC2* LOVD are indicated as 'not listed'. Previously untested variants are indicated in bold.

Exon	Variant	SIFT prediction	LOVD classification	Functional assessment
2	c.170G>A (p.R57H)	NT	not listed	unstable, pathogenic
2	c.185G>A (p.G62E)	T	unknown	probably neutral
3	c.292C>T (p.R98W)	NT	unknown	destabilising, pathogenic
3	c.307_315dup (p.105insALL)	-	unknown	destabilising, pathogenic
4	c.395C>G (p.S132C)	T	probably no pathogenicity	probably neutral

4	c.447C>G (p.F143L)	T	probably no pathogenicity	probably neutral
5	c.586G>A (p.A196T)	T	probably no pathogenicity	probably neutral
6	c.646G>A (p.E216K)	T	not listed	probably neutral
7	c.656T>C (p.L219P)	NT	not listed	destabilising, pathogenic
7	c.730T>C (p.C244R)	NT	probably pathogenic	unstable, destabilising, pathogenic
8	c.782G>C (p.R261P)	T	probably pathogenic	destabilising, pathogenic
8	c.781C>T (p.R261W)	NT	probably no pathogenicity	probably neutral
8	c.825C>G (p.N275K)	T	not listed	probably neutral
8	c.824_826del (p.275delN)	-	unknown	destabilising, pathogenic
10	c.1001T>C (p.V334A)	NT	not listed	unstable, destabilising, pathogenic
10	c.1001T>G (p.V334G)	NT	probably pathogenic	unstable, destabilising, pathogenic

10	c.1019T>C (p.L340P)	NT	not listed	pathogenic
10	c.1070C>T (p.A357V)	T	not listed	probably neutral
10	c.1100G>A (p.R367Q)	T	no known pathogenicity	probably neutral
10	c.1118A>C* (p.Q373P)	T	unknown	probably neutral (predicted splice mutation)
11	c.1235A>T* (p.E412V)	NT	unknown	probably neutral (splice mutation)
11	c.1235A>T* (p.412del8)	-	unknown	unstable, destabilising, pathogenic
11	c.1255C>T* (p.P419S)	NT	probably pathogenic	probably neutral (predicted splice mutation)
13	c.1366A>G (p.E456K)	T	not listed	probably neutral
13	c.1378G>A (p.A460T)	T	unknown	probably neutral
13	c.1385G>A (p.R462H)	NT	not listed	unstable, destabilising, pathogenic
13	c.1385_1386del	NT	not listed	unstable,

	insCT (p.R462P)			destabilising, pathogenic
13	c.1397T>C (p.L466P)	T	unknown	unstable, destabilising, pathogenic
14	c.1574A>G (p.N525S)	T	no known pathogenicity	probably neutral
15	c.1678G>A (p.V560M)	T	not listed	pathogenic
16	c.1736del78 (p.580del26)	-	unknown	unstable, destabilising, pathogenic
16	c.1790insCAC (p.597insH)	-	unknown	destabilising, pathogenic
16	c.1792T>C (p.Y598H)	T	probably pathogenic	destabilising, pathogenic
16	c.1796A>T (p.K599M)	T	pathogenic; updated to unknown	probably neutral
16	c.1820C>A (p.A607E)	T	unknown	unstable, destabilising, pathogenic
16	c.1819G>T (p.A607S)	T	not listed	probably neutral
16	c.1819G>A	T	probably no	probably neutral

	(p.A607T)		pathogenicity	
16	c.1826_1828dup p (p.609insS)	-	pathogenic	destabilising, pathogenic
16	c.1832G>A (p.R611Q)	NT	pathogenic	unstable, destabilising, pathogenic
16	c.1831C>T (p.R611W)	NT	pathogenic	destabilising, pathogenic
17	c.1841C>A* (p.A614D)	T	probably pathogenic	unstable, destabilising, pathogenic
17	c.1844T>C (p.F615S)	T	no known pathogenicity; updated to unknown	destabilising, pathogenic
17	c.1864C>T (p.R622W)	NT	unknown	unstable, destabilising, pathogenic
17	c.1882C>G* (p.R628G)	T	unknown	pathogenic
18	c.1973A>C (p.K658T)	T	not listed	probably neutral
18	c.1972_1974del (p.658delK)	-	no known pathogenicity	probably neutral

18	c.2078T>C (p.L693P)	NT	probably pathogenic	unstable, destabilising, pathogenic
18	c.2087G>A (p.C696Y)	NT	unknown	unstable, destabilising, pathogenic
20	c.2306T>A (p.V769E)	T	probably pathogenic	unstable, destabilising, pathogenic
21	c.2363T>G (p.M788R)	NT	probably pathogenic	unstable, destabilising, pathogenic
21	c.2410T>C (p.C804R)	NT	probably pathogenic	destabilising, pathogenic
21	c.2458_2460del (p.820del)	-	pathogenic	unstable, destabilising, pathogenic
21	c.2476C>A (p.L826M)	NT	no known pathogenicity	probably neutral
23	c.2666C>T (p.A889V)	NT	probably pathogenic	unstable, destabilising, pathogenic
23	c.2690T>C (p.F897S)	NT	probably pathogenic	unstable, destabilising, pathogenic

Supporting Table S3:

***TSC2* variants (amino acids 900 - 1807).** *TSC2* nucleotide changes and exon numbers are given according to the *TSC2* LOVD (<http://www.lovd.nl/TSC2>). Nucleotide numbering reflects the *TSC2* cDNA numbering (Genbank X75621; GI:450351) with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). Amino acid changes are numbered according to the sequence of the wild-type *TSC2* expression construct used [European Chromosome 16 Tuberous Sclerosis Consortium, 1993] (Genbank X75621; GI:450351). Amino acid changes according to the *TSC2* LOVD are also given, where this differs from the original sequence due to the inclusion of 23 amino acids encoded by the alternatively spliced exon 31 (Genbank X75621.1; GI:4071057). Nucleotide changes predicted to cause splicing defects are marked with an asterisk.

Amino acid substitutions predicted by SIFT to be tolerated (T) or not tolerated (NT) are indicated. Previously untested variants are indicated in bold. Links to the original references describing the different variants can be accessed via the *TSC2* LOVD. Variants not previously listed in the *TSC2* LOVD are indicated as 'not listed'.

Exon	Variant	SIFT prediction	LOVD classification	Functional assessment
23	c.2713C>G (p.R905G)	NT	probably pathogenic	pathogenic
23	c.2714G>A (p.R905Q)	NT	pathogenic	pathogenic
23	c.2713C>T	NT	pathogenic	pathogenic

	(p.R905W)			
24	c.2765T>G (p.L916R)	NT	probably pathogenic	unstable, pathogenic
25	c.2853A>T (p.R951S)	T	probably pathogenic; updated to unknown	probably neutral
25	c.2963G>C (p.R988P)	T	not listed	probably neutral
26	c.2978C>T (p.T993M)	T	probably no pathogenicity	probably neutral
26	c.3082G>A (p.D1028N)	NT	not listed	unstable, pathogenic
26	c.3095G>C (p.R1032P)	NT	probably pathogenic	pathogenic
26	c.3106T>C (p.S1036P)	NT	probably pathogenic	pathogenic
27	c.3182T>C (p.L1061P)	NT	not listed	unstable, pathogenic
27	c.3203C>A (p.T1068I)	NT	unknown	pathogenic
27	c.3224C>T (p.T1075I)	NT	unknown	probably neutral
28	c.3382C>T (p.R1122C)	T	not listed	probably neutral

29	c.3476G>T (p.R1159L)	T	unknown	unstable, probably neutral
29	c.3476G>A (p.R1159Q)	T	no known pathogenicity	unstable, probably neutral
29	c.3475C>T (p.R1159W)	T	unknown	probably neutral
29	c.3596T>G (p.V1199G)	T	unknown	unstable, pathogenic
29	c.3598C>T (p.R1200W)	NT	pathogenic	unstable, pathogenic
29	c.3605C>A (p.P1202H)	T	not listed	pathogenic
30	c.3611G>A* (p.G1204E)	NT	probably pathogenic	pathogenic
32	c.3943C>G (p.P1315A/ P1292A)	T	unknown	probably neutral
33	c.4105C>T (p.R1369W/ R1346W)	T	probably no pathogenicity	probably neutral
33	c.4225C>T (p.R1409W/ R1386W)	T	no known pathogenicity	probably neutral
33	c.4298C>T (p.S1433L/ S1410L)	T	unknown	probably neutral

33	c.4316G>A (p.G1439D/G1416D)	T	unknown	probably neutral
33	c.4490C>G (p.P1497R/P1474R)	NT	pathogenic	pathogenic
33	c.4489C>T (p.P1497S/P1474S)	T	not listed	pathogenic
33	c.4489C>A (p.P1497T/P1474T)	NT	probably pathogenic	pathogenic
34	c.4499T>G (p.V1500G/V1477G)	T	probably pathogenic	pathogenic
34	c.4525_4527del (p.1510delF/1487delF)	-	no known pathogenicity	probably neutral
35	c.4601T>A p.L1534H/L1511H)	NT	probably pathogenic	unstable, pathogenic
35	c.4604A>C (p.D1535A/D1512A)	NT	unknown	pathogenic
35	c.4643T>C (p.L1548P/L1525P)	NT	unknown	unstable, destabilising, pathogenic
36	c.4700G>T (p.G1567V /G1544V)	NT	unknown	destabilising, pathogenic
36	c.4726_4783del (p.1575del19/	-	unknown	unstable, pathogenic

	1552del19)			
36	c.4733T>C (p.L1578P/L1555P)	NT	probably pathogenic	unstable, destabilising, pathogenic
36	c.4735G>A (p.G1579S/G1556S)	NT	probably pathogenic	pathogenic
37	c.4918C>T (p.H1640Y/H1617Y)	NT	unknown	pathogenic
37	c.4925G>A (p.G1642D/G1619D)	NT	unknown	pathogenic
37	c.4927A>C (p.N1643H/N1620H)	NT	unknown	pathogenic
37	c.4928A>T (p.N1643I/N1620I)	NT	probably pathogenic	pathogenic
37	c.4929C>G (p.N1643K/N1620K)	NT	probably pathogenic	unstable, pathogenic
37	c.4928A>G (p.N1643S/N1620S)	NT	not listed	pathogenic
37	c.4937T>G (p.V1646G/V1623G)	NT	unknown	unstable, destabilising, pathogenic
38	c.5057A>C (p.Q1686P/Q1663P)	T	not listed	unstable, destabilising, pathogenic
39	c.5138G>A	NT	unknown	unstable,

	(p.R1713H/R1690H)			destabilising, pathogenic
40	c.5228G>A (p.R1743Q/R1720Q)	NT	pathogenic	pathogenic
40	c.5227C>T (p.R1743W/ R1720W)	NT	pathogenic	pathogenic
40	c.5238_5255del (p.1746del6/ 1723del6)	-	pathogenic	unstable, destabilising, pathogenic
41	c.5383C>T (p.R1795C/R1772C)	NT	no known pathogenicity	probably neutral
41	c.5386C>A (p.L1796I/L1773I)	T	probably pathogenic; updated to unknown	probably neutral